Mark. Thank you,
our XXXX. of proud in performance We’re
our made pivotal study pursued stenosis their We the of and severe of strides to TAVR studying technologies. important in Separately, was moderate milestones, as patients, aortic FDA SAPIEN our we we portfolio increasing completed a continued make develop. strategy. further for TAVR we ALLIANCE to trial and PROGRESS a and pivotal the start enrollment expansion on patients XX. were long-term executing clinical we XXXX TAVR, for and key of relentless. significant patients; in EARLY invested adoption; drivers: COVID, trial, enrollment it real-world initiated of next-generation favorable awareness, treatment progress continue Edwards our hospitals achieved particular, be positive an and by trial teams we pioneering our therapies our we In for to Although, results trial our advancing In important outcomes. technology, therapy meaningful before advance pivotal milestones in AS support significant value approval our approvals and In new investment impacted year to TMTT, received three symptoms for
In XXXX, the position Surgical we we completed keeps of our portfolio We platforms TMTT promising our our pivotal that to XXXX X,XXX our year. gaining over late of both track have learnings experiences. premium an adoption us are outcomes for pleased in important clinical with approval performance. our patients clinical Structural differentiated through also announce CLASP in pleased leadership trial that of and demonstrated enrollment our I'm to IID and commercial therapies, on of technologies. valuable treated through Each this U.S. milestone Heart, extended
around patients also life-saving and the to employees We was pandemic get hands throughout able supply our we year, our technologies And partners ensure hospital our so our that before. were the ways that one they global also more even to implemented valuable patients. support fueled commitments therapies to in benefited to I'm monitoring innovative life-saving could ongoing the Despite Most trusted patients additions ever serve critical efforts, dedicated proud through to XXXX, world technologies to importantly their our keeping challenges, say to than employees to impacted. into to another. and our advancements Edwards' not in smart our found their care. of remain from ability our the procedures
long-term before growth financial achieve to all I $X.X in lives the XX% R&D, organic into significant last month, get heard tremendous region. as are billion, bring We our like you the and this several system. as we achieved as care while patients' earnings pleased increasing increase ever highlights key increased to to infrastructure in In significant adjusted we expectations. have are per The our about the opportunity I'd to year XXXX, Now details. health driven growth to share, by helped of quarterly we financial and sales enhance at cover R&D XXXX investor our each XX%. sales Underlying investments balanced XX% outlook. conference also strengthen And convinced in value
on basis TAVR platform. global We billion of million, increase the prices that year-over-year TAVR our of $XXX we were globally, $X.X hospital billion year. with US, sales fourth TAVR sales the maintained strategy. pricing the Full selling our innovative quarter, $X.X benefits constant our therapy were global increased were resources our on technologies, our versus of disciplined procedure in end $X.X average driven grew our SAPIEN procedures global And year In our Turning billion was our TAVR results. Fourth XX% we XXXX prior TAVR were due by in strength although comparable increased to an Omicron lower $X.X as of billion line a quarter, the XX% basis fourth the currency with of basis, of awareness an intermittent original period. to challenges the guidance estimate XX% the Despite of in the sales outside our portfolio sales to growth. In and US. growth Growth pandemic at October XX% share stable. our pronounced the with financial the underlying in with quarter stable and impressive December, the on US. versus with the sales was year, was increased associated of driven by ago impact estimate expectations especially on year of of throughout an underlying
in population had procedure postponed or noticeable underlying highest access are of stenosis Outside patients. on volume impact approximately December a a to helping XX% variant hospital comparable. of to were total estimate in resources a TAVR As and number hospitals. centers, growth our provide in previously grew was broader aortic which US cases the sales an small we quarter the mentioned, fourth year-over-year the US, limited in mid as in on Growth was the basis Omicron
economically was risk that was our strong -- We're and XX. mid-teens, these region. regions. who published of was are stable. recently believe the European cost-effectiveness of low the encouraged of developments broad-based noting estimate a guidelines competitive both who over now TAVR Association are at We the dominant surgical low worth by with It's mortality. for Cardiothoracic from recent all in Several still valve broadly even We were French Japan also when long-term TAVR that demonstrated is low. definitively important which in compared across Sales represents aortic in patients international where at relatively recommend of continue SAPIEN surgical adoption was to to In mortality we patients strong, important Growth encouraged with aortic treating patients TAVR therapy X surgical to in milestones that achieved more opportunity position growth an was Surgery, replacement TAVR by bring in adoption the Edwards' severe be stenosis need. therapy growth QX. Europe, study to the in symptomatic also
least aortic in surgical was replacements. valve For procedures each TAVR comparable hospital one in with the the Japan, now performed SAPIEN. first at time, Japan the prefecture offering in number is of Furthermore, there
the the we remain reimbursement quite therapy continued excellent on we country. global of Longer adoption TAVR term, remains patients Following see of the opportunities risk, expanding surgical for throughout approval focused availability growth TAVR low the recent therapy of treatment OUS low. for as at believe we
to remain the AS moderate geographic enrollment expansion. our expansion on on indication focused symptoms the of risking before progressive therapies, AS our as Separately, heart We the earlier treatment their asymptomatic of becomes who trial, progresses. enrollment TAVR patients. optimal an pivotal to we damage addition of which PROGRESS, disease important from we irreversible completed is to than pivotal have rather patients for severe aortic we stenosis that believe treat or may determine benefit to trial their treatment have time in they QX, our some EARLY-TAVR patients In disease. In initiated this before focused
SAPIEN took XX. to trial also We product device, received In our ALLIANCE our QX, we steps advance portfolio. for our FDA TAVR next-generation to study innovative pivotal approval
and QX, number we these This patients. heart result adaptive life use XX%, of approval SAPIEN the in quality of younger December conference. in pre-stent to TAVR that for over our a year, X a in growth XXXX to reduction received continue Alterra their FDA consistent with congenital should range sales the procedures In improvement lifetime. XX% shared patients of investor we a will despite with to our summary, at start slower-than-expected to the anticipate underlying we require Additionally,
large in $XX constraints which assumes remain resource growth low outlook stabilize. and in challenges We Omicron as range. a Our to will implies turning double-digit annual XXXX, opportunity rate in COVID-related growth to compounded subside hospital XXXX, more the normalized double global early headwinds from confident billion environment this by
Turning to TMTT.
XXXX. we this to on As remain for our trial, This in us of year the PASCAL in present pivotal enrollment approval track track mitral quarter, late keeps I milestone completed with data the IID patients of regurgitation. of on half we and mentioned, degenerative US fourth Class important for second
outcomes study this approval in conference safe PASCAL continue MR Precision post-market XX-day more next-generation approval PASCAL setting. effective highlighted of a later data London of from presented. and expect the than in year. The also We System reduction to MiCLASP XXX were our post-market in patients our Valves Europe QX, PCR European At
CLASP to replacement Early on both through our for In trial in and IIF increase experience the we our for study Eos. mitral transcatheter both confidence SAPIEN with transfemoral MX our trial MISCEND of therapies progressed replacement, the disease. expand patients mitral We the also platforms. mitral our pivotal continue sub-French ENCIRCLE for EVOQUE functional enrollment experience these therapies with pivotal with
Conference tricuspid TRISCEND demonstrated the patient months. at Annual outcomes that were from six with therapies, results transcatheter early the November and to and tricuspid at sustained study EVOQUE were the Turning presented TCT favorable in
sustained rates patients. TR life reduction We measures are improvements in encouraged also by of quality by the the procedural success and and experienced significant these
pivotal regurgitation. the Europe our late trial the system patients options the II We trials, that and providing continue remain to with II of for in in EVOQUE approval symptomatic to two treatment EVOQUE prognosis with trial XXXX We and PASCAL pivotal patients very enrolling CLASP few these today. committed poor TR meaningful solutions TRISCEND pivotal make for severe and tricuspid a tricuspid tricuspid anticipate have in progress
negative the Turning quarter increased December. third despite grew adoption we sequentially from XXXX than COVID sales revenue sales the Full in million to more the $XX to impact saw of performance global year as $XX TMTT. Fourth PASCAL of the of doubled quarter, system million.
by year, As mitral the we are we investor our conference. disease diseases. PASCAL to expect we tricuspid Despite with our portfolio impact in this of and our for the with of supported global transform model. high-touch $XXX We XXXX. that by continuing in of advancing more to expand with excellent to we continue our sales patients recent We XXXX, approximately TMTT lives COVID therapies with outcomes life-threatening forward availability $X XXXX, to will opportunity of look we outlined to toward these vision committed in bringing progress patients the TMTT million patients the grow our million the groundbreaking to to to continue centers the valve Europe, to pleased and milestones for so $XXX estimate remain billion far
over year. $XXX strategy on an up We underlying for are our Heart, prior us million, In full year. Structural Surgical confident quarter of million positions global well prior year increased underlying XXXX on basis an basis sales global XX% the $XXX versus were X% sales leadership. portfolio Fourth the
valve of about to COMMENCE valve. X RESILIA supports we that especially continued worsen procedures. valve, continued hospital the The adoption growing throughout tissue technology RESILIA valve Edwards aortic and staffing sizes the valves, excellent that prioritized conduit aortic We're of remain saw MITRIS X life-saving study across to in by surgical tissue the RESILIA evidence INSPIRIS KONECT being global presented of weekend. tissue including hemodynamics at shortages the therapies aortic our We the excited US, demonstrates quarter, RESILIA Surgeons surgical Society Thoracic be years. Although, all studies Conference continue encouraged elective this at the over this
digit While range be we growth adoption technologies a full with a valves. single study growth. will mid use expect driven and our INSPIRIS versus mechanical by shows sales underlying the for economic procedure value the in of continue In year European XXXX Heart, reduction cost that to Surgical summary, our Structural premium of
treatment adoption and provide TAVR expands, choice surgeons. patients, of for innovative about options to our the ability cardiac Even leadership surgical for we're partner extend excited be global our as
global balanced lines contributions Turning the led to $XXX underlying XX% resumed. prior Critical capital Care. sales XXXX growth sales on million year. driven Full by year an basis increased from HemoSphere of by was all as product versus spending
quarter, by which for broad the Our ICU the in remained robust sustained our COVID the demand smart at for US portfolio $XXX elevated levels. also in noninvasive Fourth X% driven demand cuff, achieved TruWave ClearSight, recovery Demand above finger underlying sensors the HemoSphere. in disposable strong basis, due fourth performance of million monitoring used pre-COVID in to also both increased or including our pressure devices sales and quarter Critical Care of high hospitalizations on an Europe. remained
now our summary, conference, analytics leadership turn expect of about offering recovery to tools In of products. critical the our to monitoring. recent pipeline integration remain in And enhanced the technologies care full hemodynamic I'll creates As innovative growth our to mid-single-digit over unique further discussed and predictive we continue a investor call XXXX, for excited and Scott. a of of at strengthen we range sales underlying capabilities
